Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label safety study of riliprubart in cold agglutinin disease
NL-OMON60886Phase 1Completed
- Sponsor
- Sanofi
- Start
- Aug 2021
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of riliprubart in cold agglutinin disease (CAD) (2 arms), sponsored by Sanofi. Primary endpoint: Number of participants with treatment-emergent adverse events. Started Aug 2021; status: completed.
02
Drugs
riliprubart
03
Conditions
cold agglutinin disease (CAD)
Beyond the preview
Go deeper on NL-OMON60886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60886.